LOS ANGELES--(BUSINESS WIRE)--Kythera Biopharmaceuticals, Inc. (“Kythera”) announced today that it has initiated and completed enrollment of its Phase II study of ATX-201 for actinic keratosis (AK). The ongoing Phase II trial is a randomized, double-blind, placebo-controlled study of 48 patients being conducted in France. Subjects with actinic keratoses on the scalp and face are undergoing at least one course of treatment with ATX-201 or placebo over a 4 to 12-week period. An assessment of efficacy, safety and tolerability will be made in multiple treatment regimens based on both primary and exploratory scales.
